Can a single dose of tocilizumab clear the way for a second kidney transplant?

NCT ID NCT04779957

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 pilot study tested whether a single dose of tocilizumab, given before or after removing a failed kidney transplant, is safe and can reduce harmful antibodies that make a second transplant difficult. The study involved 18 adults who needed their kidney graft removed and hoped for another transplant. The main focus was on serious infections, but researchers also looked at overall complications and antibody levels one year later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tocilizumab
What this could lead to
If it works, this could help people who lose a kidney transplant have a better chance of getting a second one by reducing immune system barriers.
What could go wrong
This is a small, early-phase pilot study with only 18 participants, so results may not apply to everyone. The drug may also increase the risk of serious infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.